Athira Pharma Surges on $90M Financing and Exclusive Lasofoxifene License
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Athira Pharma Inc (NASDAQ: ATHA) is a clinical‐stage biopharmaceutical company headquartered in Bothell, Washington. Founded in 2011, the company focuses on developing small‐molecule therapies in oncology and neurology. Its pipeline includes lasofoxifene for estrogen receptor‐positive metastatic breast cancer and ATH-1105 for neurodegenerative diseases.
Corporate Structure and Leadership
Athira Pharma employs approximately 51–200 staff across research, clinical development, and corporate functions. Mark Litton, PhD, MBA, has served as President and Chief Executive Officer since October 21, 2021. The Board of Directors is chaired by Kelly Romano, founder and CEO of BlueRipple Capital, and includes industry professionals such as Joe Edelman of Perceptive Advisors and John Fluke Jr.
Biopharmaceuticals by little plant
Developments and News
- December 17, 2025: Shares closed at $6.82, a 64.93% increase from the prior close, on a volume of 7,895,498.
- December 18, 2025: Athira entered an exclusive license agreement for lasofoxifene, a selective estrogen receptor modulator now in the ELAINE-3 Phase 3 trial for ER+ HER2- metastatic breast cancer.
- December 18, 2025: The company raised $90 million in an upfront private placement of common stock and warrants, with the warrants exercisable for up to an additional $146 million upon achievement of designated clinical and regulatory milestones. The financing was co-led by Commodore Capital, Perceptive Advisors, and TCGX, with participation from ADAR1, Blackstone Multi-Asset Investing, Kalehua Capital, Ligand Pharmaceuticals, NEA, Spruce Street Capital, and 9vc.
- Early 2026: Athira plans to initiate a Phase 2 trial of ATH-1105 in patients with amyotrophic lateral sclerosis (ALS), following data presented at the 4th Annual ALS Drug Development Summit in May 2025.
- December 18, 2025: The company filed an amended Form 8-K (8-K/A) reporting updates to Items 1.01, 3.02, 7.01, 8.01, and 9.01.
Financial and Strategic Analysis
| Metric | Value |
|---|---|
| Share Price (12/17/2025) | $6.82 (+64.93%) |
| Average Daily Volume (30 day) | 30,063 shares |
| Market Capitalization (intraday) | $16.3 million |
| Price/Book (MRQ) | 0.61 |
| Beta (5Y Monthly) | 2.96 |
| Cash (MRQ) | $25.2 million |
| Total Debt/Equity (MRQ) | 3.4% |
| Net Loss (TTM) | –$37.7 million |
Athira does not currently generate product revenues and finances operations through equity issuances and partnership agreements. The financing on December 18, 2025, secures capital for ongoing ELAINE-3 and planned ATH-1105 Phase 2 studies. A modest market capitalization and elevated beta reflect typical volatility in the biotechnology sector, while a price/book ratio below 1.0 indicates the shares are trading at a discount to net asset value.
Market Position and Industry Context
In oncology, Athira’s lasofoxifene program targets patients with ESR1-mutated, ER+ HER2- breast cancer who have progressed on standard endocrine therapies. Competitive agents include CDK4/6 inhibitors and selective estrogen receptor degraders. In neurology, ATH-1105 and fosgonimeton aim to modulate the hepatocyte growth factor system for diseases such as ALS, Alzheimer’s, and Parkinson’s diseases—areas with significant unmet medical needs but considerable regulatory and clinical challenges. Athira’s small‐molecule approach offers potential advantages in administration and manufacturing compared to prevailing biologics and gene therapies.
tl;dr
On December 17, 2025, ATHA stock increased 64.93% to $6.82 following news of an exclusive lasofoxifene license and a $90 million private placement with potential for up to $146 million in milestone funding. The ELAINE-3 trial is underway, and a Phase 2 study for ATH-1105 in ALS patients is planned for early 2026. The company filed an amended 8-K report on December 18, 2025, detailing these developments and other updates.